Use of Sodium‐Glucose Cotransporter‐2 Inhibitors and Angiotensin Receptor‐Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real‐World Data

Background Contemporary use of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) and angiotensin receptor‐neprilysin inhibitors (ARNi) in patients with atrial fibrillation (AF) and heart failure (HF) has not been described. Methods and Results We analyzed the MarketScan databases for the period Jan...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Alvaro Alonso, Alanna A. Morris, Ashley I. Naimi, Aniqa B. Alam, Linzi Li, Vinita Subramanya, Lin Yee Chen, Pamela L. Lutsey
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2024-03-01
coleção:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Assuntos:	angiotensin receptor‐neprilysin inhibitors atrial fibrillation heart failure sodium‐glucose cotransporter‐2 inhibitors
Acesso em linha:	https://www.ahajournals.org/doi/10.1161/JAHA.123.032783
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!